View Older Stories View More Recent Stories

Feb 28, 2024 01:30AM AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
Feb 28, 2024 12:11AM AbbVie (ABBV) partners with OSE Immunotherapeutics to develop Novel Monoclonal Antibody
Feb 28, 2024 12:05AM AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
Feb 27, 2024 08:00AM AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
Feb 27, 2024 07:45AM U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
Feb 27, 2024 07:45AM U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Feb 26, 2024 07:55PM Genmab (GMAB) FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab
Feb 26, 2024 07:45PM U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Feb 22, 2024 08:05AM AbbVie (ABBV) and Tentarix Collaborate Over Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
Feb 22, 2024 08:05AM AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
Feb 21, 2024 08:00AM BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs
Feb 20, 2024 09:02AM AbbVie (ABBV) Appoints Robert A. Michael as CEO
Feb 20, 2024 09:00AM AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
Feb 19, 2024 08:30AM AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
Feb 15, 2024 12:03PM AbbVie Declares Quarterly Dividend
Feb 15, 2024 08:45AM Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
Feb 12, 2024 07:38AM AbbVie (ABBV) Completes Acquisition of ImmunoGen (IMGN)
Feb 12, 2024 07:37AM AbbVie Completes Acquisition of ImmunoGen
Feb 2, 2024 07:36AM AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Jan 25, 2024 03:00AM Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024
Jan 23, 2024 08:00AM Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.
Jan 9, 2024 05:28AM AbbVie (ABBV) Launches PRODUODOPA in the EU
Jan 9, 2024 02:00AM AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union
Jan 8, 2024 08:05AM AbbVie (ABBV) Reports Lutikizumab Showed Positive Results in a Phase 2 Trial
Jan 8, 2024 08:05AM Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Jan 4, 2024 08:45AM AbbVie (ABBV) and Umoja Biopharma Collaborate to Develop Novel In-Situ CAR-T Cell Therapies
Jan 4, 2024 08:45AM AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
Jan 4, 2024 08:00AM AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
Jan 2, 2024 08:00AM AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 9, 2023 12:00PM New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Dec 9, 2023 12:00PM New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Dec 6, 2023 04:31PM AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $45 Per Share, $8.7 Billion Deal
Dec 6, 2023 04:30PM AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
Dec 5, 2023 08:46AM AbbVie (ABBV), BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
Dec 5, 2023 08:45AM AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
Nov 30, 2023 07:31AM AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $31.26 Per Share, $10.1 Billion
Nov 30, 2023 07:30AM AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
Nov 29, 2023 08:46AM AbbVie (ABBV) Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin for Patients with Previously Treated NSCLC
Nov 29, 2023 08:45AM AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Nov 27, 2023 07:01AM AbbVie (ABBV) Reports FDA and EMA Updates for Epcoritamab
Nov 27, 2023 07:00AM AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
Nov 20, 2023 08:45AM Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever
Nov 16, 2023 07:02AM AbbVie (ABBV) Reports Publication Showing UBRELVY Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
Nov 16, 2023 07:00AM Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
Nov 8, 2023 08:45AM Natrelle® Unveils New "For Every BODY" Campaign
Nov 1, 2023 08:45AM BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before
Oct 27, 2023 07:38AM AbbVie Reports Third-Quarter 2023 Financial Results
Oct 24, 2023 08:31AM Allergan (ABBV) Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Oct 24, 2023 08:30AM Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Oct 19, 2023 08:45AM Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project
View More Recent Stories View Older Stories